Lupus erythematosus - Qizil Qizil Yuguruk
☆ Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
Bir oz binafsha rangli eritema shaklida namoyon bo'ladi.
Odatda yuzda paydo bo'ladigan kapalak toshmasi.
References
Cutaneous lupus erythematosus (CLE) ni aniqlash va tasniflash diagnostik qiyinchiliklarni keltirib chiqaradi, uni teri aralashuvi bilan systemic lupus erythematosus dan ajratib turadi. Oxirgi tadqiqotlar CLE ning irsiy, ekologik va immunologik omillariga oydinlik kiritdi. Giyohvand moddalarni induktsiya qilish, ayniqsa, CLE uchun eng muhim tetiklardan biri sifatida paydo bo'ldi. Davolash topikal va tizimli terapiyani o'z ichiga oladi, shu jumladan belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 kabi istiqbolli biologik preparatlar, klinik tadkikotlarda samaradorligi isbotlangan.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) turli teri muammolarini qamrab oladi, ularning ba'zilari kengroq sog'liq muammolari bilan bog'liq bo'lishi mumkin. U har xil turlarga bo'lingan, masalan, acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus dan iborat.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus - tananing turli qismlariga ta'sir qilishi mumkin bo'lgan otoimmün kasalliklar guruhi. Ba'zi turlari, masalan, systemic lupus erythematosus (SLE) , bir nechta organlarga ta'sir qiladi, boshqalari, masalan, cutaneous lupus erythematosus (CLE) , asosan teriga ta'sir qiladi. Biz turli xil CLE turlarini klinik belgilar, to'qimalarni tekshirish va qon testlari aralashmasi asosida tasniflaymiz, ammo odamlar o'rtasida juda ko'p farqlar mavjud. Teri muammolari ko'pincha quyosh nuriga ta'sir qilish, chekish yoki ba'zi dorilar kabi omillar tufayli rivojlanadi.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
qizil qizil yuguruk (lupus erythematosus) sababi aniq emas. Bir xil egizaklar orasida, agar bittasi kasal bo'lsa, ikkinchisi ham bo'lish ehtimoli 24% ni tashkil qiladi. Ayol jinsiy gormonlari, quyosh nuri, chekish, D vitamini etishmovchiligi va ayrim infektsiyalar ham xavfni oshiradi deb ishoniladi.
Davolashda NSAIDlar, kortikosteroidlar, immunosupressantlar, gidroksiklorokin va metotreksat bo'lishi mumkin. Kortikosteroidlar samarali bo'lsa-da, uzoq muddatli foydalanish yon ta'sirga olib keladi.